| Bonus Resources.txt | 102.4 B | ||
| Get Bonus Downloads Here.url | 204.8 B | ||
| ~Get Your Files Here ! | |||
| 1 - Molecule to Market | |||
| 1 - Welcome to the course.en_US.srt | 3.2 KB | ||
| 1 - Welcome to the course.mp4 | 87.3 MB | ||
| 10 - Drug Development Phases and Clinical Trials | |||
| 11 - The Regulatory Framework | |||
| 2 - What Is the Biopharmaceutical Industry | |||
| 3 - Key Industry Players and Stakeholders | |||
| 10 - Inroduction (Description).html | 614.4 B | ||
| 10 - Inroduction.en_US.srt | 2.6 KB | ||
| 10 - Inroduction.mp4 | 56.6 MB | ||
| 11 - The Ecosystem.en_US.srt | 3.4 KB | ||
| 11 - The Ecosystem.mp4 | 70.8 MB | ||
| 12 - CDMOs and CROs.en_US.srt | 3.4 KB | ||
| 12 - CDMOs and CROs.mp4 | 82.6 MB | ||
| 13 - Regulatory Bodies.en_US.srt | 1.2 KB | ||
| 13 - Regulatory Bodies.mp4 | 30.2 MB | ||
| 14 - Healthcare Providers and Patients.en_US.srt | 2.2 KB | ||
| 14 - Healthcare Providers and Patients.mp4 | 49.5 MB | ||
| 15 - Investors.en_US.srt | 1 KB | ||
| 15 - Investors.mp4 | 19.7 MB | ||
| 16 - Highly Functional Network.mp4 | 51.5 MB | ||
| 4 - Active Pharmaceutical Ingredients (API) | |||
| 17 - What is an API.en_US.srt | 2.6 KB | ||
| 17 - What is an API.mp4 | 61.6 MB | ||
| 18 - Small Molecules vs Biologics.en_US.srt | 3.6 KB | ||
| 18 - Small Molecules vs Biologics.mp4 | 71.9 MB | ||
| 19 - The Quality Trinity - Purity, Potency and Stability.en_US.srt | 2.8 KB | ||
| 19 - The Quality Trinity - Purity, Potency and Stability.mp4 | 68.1 MB | ||
| 20 - Summary.en_US.srt | 3.5 KB | ||
| 20 - Summary.mp4 | 72.6 MB | ||
| 5 - Monoclonal Antibodies (mAbs) | |||
| 1 - Quiz - API, mABs.html | 19.6 KB | ||
| 21 - What is Antibody and Immune System.en_US.srt | 2.7 KB | ||
| 21 - What is Antibody and Immune System.mp4 | 49.8 MB | ||
| 22 - what is Monoclonal Antibody.en_US.srt | 2.3 KB | ||
| 22 - what is Monoclonal Antibody.mp4 | 42.9 MB | ||
| 23 - Precision vs Brute forces - mABs vs Chemotherapy.en_US.srt | 4.7 KB | ||
| 23 - Precision vs Brute forces - mABs vs Chemotherapy.mp4 | 97 MB | ||
| 24 - Where mAbs are used and future growth.en_US.srt | 1.1 KB | ||
| 24 - Where mAbs are used and future growth.mp4 | 21.2 MB | ||
| 25 - The Business and Clinical Power of Monoclonal Antibodies.en_US.srt | 3.9 KB | ||
| 25 - The Business and Clinical Power of Monoclonal Antibodies.mp4 | 65.5 MB | ||
| 26 - How mABs manufactured - Living factories.en_US.srt | 5.5 KB | ||
| 26 - How mABs manufactured - Living factories.mp4 | 120.5 MB | ||
| 6 - Highly Potent Active Pharmaceutical Ingredient ( HPAPI) | |||
| 27 - What Makes an API Highly Potent.en_US.srt | 1.8 KB | ||
| 27 - What Makes an API Highly Potent.mp4 | 38 MB | ||
| 28 - OEB (Occupational Exposure Band) and Market Drivers.en_US.srt | 2.4 KB | ||
| 28 - OEB (Occupational Exposure Band) and Market Drivers.mp4 | 51.3 MB | ||
| 29 - Power, Precision and Convergence.en_US.srt | 2.2 KB | ||
| 29 - Power, Precision and Convergence.mp4 | 47.9 MB | ||
| 7 - Antibody Drug Conjugate (ADC) | |||
| 30 - What is ADC.en_US.srt | 2.4 KB | ||
| 30 - What is ADC.mp4 | 55.9 MB | ||
| 31 - How It Works — Step by Step.en_US.srt | 4.6 KB | ||
| 31 - How It Works — Step by Step.mp4 | 94.2 MB | ||
| 32 - ADC Manufacturing.en_US.srt | 1.9 KB | ||
| 32 - ADC Manufacturing.mp4 | 40.9 MB | ||
| 33 - The clinical and commercial impact of ADCs.en_US.srt | 2.3 KB | ||
| 33 - The clinical and commercial impact of ADCs.mp4 | 48.5 MB | ||
| 8 - Gene And Cell Therapies | |||
| 2 - Quiz - Cell and Gene Therapy.html | 20.2 KB | ||
| 34 - Cell, DNA and Gene The Blueprint.en_US.srt | 7.1 KB | ||
| 34 - Cell, DNA and Gene The Blueprint.mp4 | 131.6 MB | ||
| 35 - Gene and Cell Therapy.en_US.srt | 2.1 KB | ||
| 35 - Gene and Cell Therapy.mp4 | 48.8 MB | ||
| 36 - Viral vectors (AAV), CRISPR scissors.en_US.srt | 2.6 KB | ||
| 36 - Viral vectors (AAV), CRISPR scissors.mp4 | 63 MB | ||
| 37 - CAR-T.en_US.srt | 4.2 KB | ||
| 37 - CAR-T.mp4 | 94.9 MB | ||
| 38 - mRNA Vaccine.mp4 | 77.1 MB | ||
| 39 - The Market and the Challenges.mp4 | 50.2 MB | ||
| 9 - Biosimilars | |||
| 40 - What is a biosimilar.en_US.srt | 1 KB | ||
| 40 - What is a biosimilar.mp4 | 28.9 MB | ||
| 41 - How Biosimilars Are Developed and Approved.en_US.srt | 2 KB | ||
| 41 - How Biosimilars Are Developed and Approved.mp4 | 50.7 MB | ||
| 42 - Interchangeability and the Market Outlook.en_US.srt | 4.1 KB | ||
| 42 - Interchangeability and the Market Outlook.mp4 | 96.9 MB | ||
| 6 - Beyond the chemistry.en_US.srt | 2.3 KB | ||
| 6 - Beyond the chemistry.mp4 | 50.3 MB | ||
| 7 - Biologics vs Small molecule.en_US.srt | 7.3 KB | ||
| 7 - Biologics vs Small molecule.mp4 | 149.4 MB | ||
| 8 - Global market size and growth.en_US.srt | 1.9 KB | ||
| 8 - Global market size and growth.mp4 | 42.1 MB | ||
| 9 - Importance to healthcare.en_US.srt | 5.6 KB | ||
| 9 - Importance to healthcare.mp4 | 142.3 MB | ||
| 49 - The Biopharma operating system.en_US.srt | 1.9 KB | ||
| 49 - The Biopharma operating system.mp4 | 36.7 MB | ||
| 50 - Global Regulatory Bodies.en_US.srt | 3.5 KB | ||
| 50 - Global Regulatory Bodies.mp4 | 76.4 MB | ||
| 51 - FDA Review Pathways.en_US.srt | 4.1 KB | ||
| 51 - FDA Review Pathways.mp4 | 77.9 MB | ||
| 52 - Good Manufacturing Practice — GMP.en_US.srt | 3.2 KB | ||
| 52 - Good Manufacturing Practice — GMP.mp4 | 67.4 MB | ||
| 53 - Intellectual Property Protection.en_US.srt | 4.3 KB | ||
| 53 - Intellectual Property Protection.mp4 | 93.3 MB | ||
| 43 - Drug Development Introduction.en_US.srt | 1.4 KB | ||
| 43 - Drug Development Introduction.mp4 | 26.2 MB | ||
| 44 - drug development pipeline.en_US.srt | 2.4 KB | ||
| 44 - drug development pipeline.mp4 | 41.4 MB | ||
| 45 - Discovery and Preclinical.en_US.srt | 3.9 KB | ||
| 45 - Discovery and Preclinical.mp4 | 69.4 MB | ||
| 46 - Clinical Trials.en_US.srt | 5.5 KB | ||
| 46 - Clinical Trials.mp4 | 98 MB | ||
| 47 - Regulatory.en_US.srt | 1.8 KB | ||
| 47 - Regulatory.mp4 | 36.5 MB | ||
| 48 - Post-Market Surveillance.en_US.srt | 2 KB | ||
| 48 - Post-Market Surveillance.mp4 | 41 MB | ||
| 2 - About the course.en_US.srt | 3.2 KB | ||
| 2 - About the course.mp4 | 71.2 MB | ||
| 3 - What you will learn.en_US.srt | 8.8 KB | ||
| 3 - What you will learn.mp4 | 174.3 MB | ||
| 4 - Who this course is for.en_US.srt | 716.8 B | ||
| 4 - Who this course is for.mp4 | 22.9 MB | ||
| 5 - Start the journey.en_US.srt | 1.6 KB | ||
| 5 - Start the journey.mp4 | 30.3 MB |
Biopharmaceutical: Biologics, Drug Development-Manufacturing
https://WebToolTip.com
Published 6/2026
MP4 | Video: h264, 1920x1080 | Audio: AAC, 44.1 KHz, 2 Ch
Language: English + subtitle | Duration: 1h 51m | Size: 3.4 GB
Learn biologics, APIs, mABs, ADCs, gene and Cell therapy, biosimilars, clinical trials, GMP, manufacturing, and markets.
What you'll learn
Explain how a drug moves from discovery through clinical trials, regulatory approval, manufacturing, and market launch — in industry language
Identify the key players — Big Pharma, biotech, CROs, CDMOs, payers, and regulators — and how they each contribute to drug development
pply biopharma knowledge as an investor, product manager, policy professional, or career changer entering the life sciences industry
Distinguish between small molecules, biologics, mAbs, ADCs, gene therapies, and biosimilars — what makes each unique and how each is made
Requirements
No prior biology or science background required — all concepts are explained from first principles with plain-language analogies
All Comments